Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Editas Medicine, Inc.NASDAQ: EDIT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.83M fell 89.4% year over year, behind the -62.3% change in trailing-twelve-month research & development. Sequentially, it fell 89.7% from the prior quarter. Over 3 fiscal years it compounded at -19.9% a year.
Context
- Research & development amounted to 222.0% of revenue in FY2025, down 394.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -89.4% toward the trailing-twelve-month pace of -62.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 89.95M USD
- Year-over-year change
- -54.9%
- 4-year CAGR
- -10.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 89.95M | -54.9% |
| FY2024 | 2024-12-31 | 199.25M | +12.2% |
| FY2023 | 2023-12-31 | 177.65M | +1.5% |
| FY2022 | 2022-12-31 | 174.96M | +22.8% |
| FY2021 | 2021-12-31 | 142.51M | — |
Research & Development vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's LTM Mar 2026 research & development of $66.19M is the 7th highest of the 9 companies compared; the peer median is $145.85M.
- Its year-over-year change of -62.3% is the lowest of 9, against a peer median of -6.6%.
- Research & development amounts to 171.1% of revenue for EDIT, versus a peer median of 695.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Sep 2026 | $283.28M | +1.6% | -16.9% | 1125.4% | |
| LTM Mar 2026 | $154.18M | -2.5% | +22.8% | 3822.0% | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| LTM Mar 2026 | $19.2M | +1.2% | +17.6% | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding EDIT) | $145.85M | -6.6% | +7.5% | 695.1% | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.54M | 19.71M | 78.12M | 32.31M | 40.52M |
| Cost of Revenue | 5.05M | 6.34M | 6.06M | 199.25M | 0 |
| Gross Profit | 20.49M | 13.38M | 72.06M | (166.93M) | 40.52M |
| Gross Margin | 80.2% | 67.9% | 92.2% | -516.6% | 100.0% |
| Research & Development | 142.51M | 174.96M | 177.65M | 199.25M | 89.95M |
| Selling, General & Admin | 76.18M | 70.7M | 69.65M | 71.99M | 49.9M |
| Operating Expenses | 213.64M | 239.33M | 241.24M | 84.22M | 139.86M |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| EBITDA | (187.45M) | (214.1M) | (147.16M) | (233.11M) | (148.61M) |
| EBITDA Margin | -733.8% | -1086.1% | -188.4% | -721.4% | -366.8% |
| Operating Income | (193.15M) | (225.95M) | (169.18M) | (251.15M) | (99.34M) |
| Operating Margin | -756.1% | -1146.3% | -216.6% | -777.2% | -245.2% |
| Interest Income | 607K | 5.52M | 17.57M | 14.06M | 8.31M |
| Interest Expense | 0 | 0 | 0 | 0 | 6.17M |
| Other Income / Expenses | 644K | 5.52M | 15.96M | 14.06M | (60.72M) |
| Income Before Tax | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Pre-Tax Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Net Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| EPS (Basic) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| EPS (Diluted) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| Weighted Avg Shares | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
| Weighted Avg Shares (Diluted) | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.